UNSPSC 51334506: Cyprodenate maleate

This classification denotes a cns stimulant C13H25NO2.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZOZ0RPZ001, chemically known as cyclohexanepropanoic acid, 2-(dimethylamino)ethyl ester, (2z)-2-butenedioate (1:1), but more generally known as cyprodenate maleate, which bears US NIH Compound Identifier 56843760. Most nations, for tariff and trade purposes, schedule cyprodenate maleate under HS 29221980 and SITC 51461. As of Q4 2014, CYPRODENATE MALEATE remains US FDA's Preferred Term for this commodity.

SMILES: CN(C)CCOC(=O)CCC1CCCCC1.C(=C\C(=O)O)\C(=O)O.

UNSPSC 51334506 Cyprodenate maleate is a Commodity code that in practice covers pharmaceutical products and therapeutic agents procured by state and local health agencies, though the recent opportunities block shows no direct solicitations for cyprodenate maleate itself. Instead, state and local governments under related pharmaceutical procurement codes are sourcing naloxone, generic multi-source pharmaceuticals, and over-the-counter products through competitive bidding and cooperative purchasing arrangements. The issuing bodies include county health departments, state health and human services commissions, and multi-state cooperative purchasing alliances that aggregate demand across state and local participants. Work ranges from direct product procurement for community health initiatives to manufacturer agreements for distribution through authorized wholesaler networks and direct-to-manufacturer prescription programs.

Recent activity centers on Florida, Minnesota, Oregon, and Texas. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually for quarterly delivery, with a response deadline of July 26, 2023. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities including Oregon, with proposals due March 26, 2026; vendors must work through three authorized wholesalers and comply with cGMP, DSCSA, and FDA requirements. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription program capabilities, signaling future formal procurement. The code shows active state and local procurement but limited visibility into cyprodenate maleate specifically.